CytoDyn (CYDY)
(Delayed Data from OTC)
$0.16 USD
0.00 (-1.00%)
Updated Sep 26, 2024 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
CytoDyn Inc. [CYDY]
Reports for Purchase
Showing records 61 - 80 ( 82 total )
Company: CytoDyn Inc.
Industry: Medical - Drugs
Data Monitoring Committee Recommends Continuation of Phase 2b/3 Trial; Reiterate Buy and $1.50 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
PRO 140 FDA Meeting Update; Orphan Drug Designation in GvHD; Reiterate Buy and Lowering Price Target to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Pivotal Combo Trial Completes Planned Enrollment; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Pivotal Combo Trial Completes Planned Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Pivotal Combo Trial Data Readout in July; FY2017 3Q Results; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Pivotal Combo Trial Data Readout in July FY2017 3Q Results.
Provider: H.C. Wainwright & Co., Inc.
Company: CytoDyn Inc.
Industry: Medical - Drugs
Phase 3 Combo Trial Efficacy Data in 1H 2017; BLA Submission in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: CytoDyn Inc.
Industry: Medical - Drugs
Phase 3 Combo Trial Efficacy Data in 1H 2017; BLA Submission in 2017; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: CytoDyn Inc.
Industry: Medical - Drugs
First Patients Treated in Phase 3 Monotherapy Trial of PRO 140; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: CytoDyn Inc.
Industry: Medical - Drugs
First Patients Treated in Phase 3 Monotherapy Trial of PRO 140; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: CytoDyn Inc.
Industry: Medical - Drugs
Company: CytoDyn Inc.
Industry: Medical - Drugs
Threshold Lowered for Pivotal PRO 140 Combo Trial; Reiterate Buy, Raising Price Target to $2.00
Provider: Rodman & Renshaw, Co.
Company: CytoDyn Inc.
Industry: Medical - Drugs
Threshold Lowered for Pivotal PRO 140 Combo Trial; Reiterate Buy, Raising Price Target to $2.00
Provider: H.C. Wainwright & Co., Inc.
Company: CytoDyn Inc.
Industry: Medical - Drugs
We are Initiating Coverage at Buy with $1.60 Price Target
Provider: Rodman & Renshaw, Co.
Company: CytoDyn Inc.
Industry: Medical - Drugs
Potential Best-in-Class Anti-HIV Antibody Candidate; Initiating at Buy with $1.60 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: CytoDyn Inc.
Industry: Medical - Drugs
Company: CytoDyn Inc.
Industry: Medical - Drugs
Company: CytoDyn Inc.
Industry: Medical - Drugs
We initiate coverage of CytoDyn Inc. with a price target of $3.40
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: CytoDyn Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: CytoDyn Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G